T-CURX is a German, venture backed, private Biotech company headquartered in Würzburg, with additional labs and offices in Munich, Bavaria. T-CURX has the ambition to democratize autologous CAR-T cell therapies by leveraging its proprietary non-viral CAR-T cell technologies for developing in vivo CAR-T and bedside-manufatured CAR-T therapies, in order to make CAR-T therapies more accessible and affordable to cancer patients. T-CURX’ CAR-T technology is based on T cell targeted LNP delivery of Sleeping Beauty transposon vectors allowing stable CAR expressing CAR-T cells in patients in vivo, in contrast to transient mRNA-based approaches, and without the need of complex, expensive and immunogenic viral vector systems. 

T-CURX has also pursuing development of clinical CAR-T pipeline programs against a novel target in AML and CLL, while two additional follow-on CAR-T pipeline programs target novel cross-entity targets expressed both in hematological malignancies, as well as solid tumor indications.

T-CURX was spun-out from the academic research group of T-CURX' co-founder Prof. Michael Hudecek (MD) University Clinics Würzburg, Germany, and was co-founded by Prof. Christoph Rader (PhD) (member of the scientific advisory board) amd Ulf Grawunder (PhD), who is serving as CEO of the company. 

T-CURX is also supported by a syndicate of international investors, including BioMedVC as lead-investor, Highlight Capital, i&iBioFund and Bayernkapital as co-investors and also by scientific key opinion leaders and Biotech-industry veterans in T-CURX' Advisory Boards with proven track records in developing innovative medicines in the fields of immunology and cancer.